Tectonic Therapeutic, Inc. Common Stock
TECXTectonic Therapeutic, Inc. (TECX) is a biotechnology company focused on developing innovative therapies for neurological and psychiatric disorders. It aims to capitalize on its proprietary drug discovery platform to identify and develop novel compounds that address unmet medical needs in areas such as neurodegeneration and mental health conditions.
Company News
Biotechnology company Tectonic Therapeutic reported a wider Q2 2025 net loss of $20.0 million, driven by increased clinical trial activities for its lead drug TX45 targeting pulmonary hypertension. Despite higher expenses, the company maintains a strong cash position of $287.4 million, with runway projected into Q4 2028.
Tectonic Therapeutic announced positive results from a Phase 1b clinical trial of its lead asset TX45 in patients with Group 2 Pulmonary Hypertension in Heart Failure with preserved Ejection Fraction (PH-HFpEF). The data confirmed TX45's tolerability and showed improvements in left ventricular function and pulmonary hemodynamics.
Tectonic Therapeutic announced positive results from the Phase 1a clinical trial of its lead asset, TX45, a long-acting, Fc-relaxin fusion protein. The results support further development of TX45 for the treatment of Group 2 Pulmonary Hypertension in Heart Failure with Preserved Ejection Fraction (PH-HFpEF).
Tectonic Therapeutic announced favorable Phase 1a results for its lead program TX45, a long-acting relaxin fusion protein, in the treatment of Group 2 Pulmonary Hypertension in Heart Failure with Preserved Ejection Fraction (PH-HFpEF). The results showed TX45 was well-tolerated with no observed immunogenicity and demonstrated a favorable PK/PD re...
